Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2025

Genmab — Maj 2025

Planlagt Fastgjort Låst Flyttet Genmab
308 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #282

    @M_T_A here you can monitor a bit what is happening, but this will probably take a long time, i don't expect to hear any news for the next year...
    https://www.pacermonitor.com/public/case/57357486/AbbVie_Inc_v_Genmab_AS_et_al

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #283

      Die AbbVie-Aktie könnte bald neuen Rückenwind aus dem Onkologie-Portfolio erhalten. Denn Partner Genmab präsentiert auf der diesjährigen ASCO-Konferenz bahnbrechende Langzeitdaten zu Epcoritamab https://www.aktiencheck.de/news/Artikel-AbbVie_Aktie_Beeindruckende_Ertragserhoehung-18589388

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #284

        Shicheng Guo
        @ShihchengGuo
        New from Stanford & Genmab: UniTox uses GPT-4o to extract drug-induced toxicities from 2,400+ FDA labels into a structured dataset. https://x.com/ShihchengGuo/status/1926138781318385917

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #285

          a bit more on - Insourcing Cell-line Development Streamlines Antibody Biomanufacturing - https://www.genengnews.com/topics/bioprocessing/insourcing-cell-line-development-streamlines-antibody-biomanufacturing

          1 Reply Last reply
          0
          • M Offline
            M Offline
            M_T_A
            wrote on sidst redigeret af
            #286

            @EL thank you so much.

            1 Reply Last reply
            0
            • P Offline
              P Offline
              ProinvestorNEWS
              wrote on sidst redigeret af
              #287

              Genmabs fremtidige salg af epcoritamab https://proinvestor.com/boards/126539

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #288

                GEN1057 moves expected completion dates a year earlier, never really know what it means; either recruitment is going superfast or patients can stay on the drug much shorter as anticipated... anyway, we'll know earlier https://clinicaltrials.gov/study/NCT06573294?tab=history&a=7&b=8#version-content-panel

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #289

                  As the 1057 study is a small phase 1 FIH study the goal is not to look at long term data so in a sense only positive if they can reach conclusions a bit sooner, I guess

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    gentogen
                    wrote on sidst redigeret af
                    #290

                    It would be nice i their laser sharp focus for once would be positive...

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #291

                      Do we know if all patients have been enrolled?

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #292

                        probably
                        not yet; the status is still 'recruiting' and 2 recruitment centers were just added

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #293

                          Abbvie arbejder med nye payloads med bedre virkning deres allerede godkendte EMRELIS™ (telisotuzumab vedotin-tllv). Nyt stof ABBV-
                          400 (Telisotuzumab adizutecan) er værd at følge https://news.abbvie.com/2025-05-27-AbbVie-Features-New-Data-Across-Difficult-to-Treat-Solid-Tumors-and-Blood-Cancers-at-ASCO-2025,-Highlighting-Breadth-and-Depth-of-its-Oncology-Portfolio

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #294

                            Genmab arbejder med samme indikationer med acasunlimab og nok mere sammenligneligt med deres ADC stof fra Profound - GEN1286

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #295

                              ABBV-400 stammer fra Immunogen købet til $10bn. ABBV-400 har DAR 6 og artiklen der er linket til nævner SAE som noget vi skal holde øje med https://www.oncologypipeline.com/apexonco/asco-2024-preview-jury-still-out-abbvies-cancer-push Husk at Elahere som også kommer fra nævnte køb også har problematiske SAE (2% fatale). Rina-S er konkurrent til Elahere. Sandelig spændende for Abbvie 🙂

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #296

                                Maj Status: NVIDIA, toldsatser, Novo, Zealand Pharma, Gubra, Genmab, Embla Kort video: https://proinvestor.com/boards/126575

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  LP90
                                  wrote on sidst redigeret af
                                  #297

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #298

                                    Godmorgen 🙂

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Stroka
                                      wrote on sidst redigeret af
                                      #299

                                      God morgen 🙂

                                      1 Reply Last reply
                                      0
                                      • B Offline
                                        B Offline
                                        bibob
                                        wrote on sidst redigeret af
                                        #300

                                        God morgen 🙂

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #301

                                          great start of ASCO for Biontech, -5%, Sanofi, -6%, Regeneron, -18% and Summit -24%, dragging this disastrous sector down again 😞

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper